Form 4: Terns Pharma Director Opts for Equity Over Cash

Terns Pharmaceuticals Director Jill M. Quigley elected to receive stock options valued at $45,000 in lieu of her 2026 cash retainer fee.

Summary

• Jill M. Quigley, a Director at Terns Pharmaceuticals, Inc. (TERN), acquired 1,697 stock options.
• The transaction date for this acquisition was February 1, 2026.
• The options have an exercise price of $34.6 per share.
• These options were issued under the Issuer's Non-Employee Director Compensation Policy.
• The options were received in lieu of a $45,000 cash retainer fee for the year 2026.
• The options will vest as to 1/12th of the total shares monthly, starting from January 1, 2026, and will be fully vested by January 1, 2027.
• The expiration date for these stock options is January 31, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's choice for equity compensation over cash indicates confidence in the company's long-term prospects and aligns their interests with shareholders.

Positives

• A director's election to receive equity compensation instead of cash aligns their financial interests with those of the shareholders, demonstrating confidence in the company's future performance.
• The long vesting schedule (over 12 months) and a 10-year expiration period for the options encourage long-term commitment and strategic decision-making from the director.

Future Outlook

The stock options granted to Director Jill M. Quigley are scheduled to vest monthly over the course of 2026, with full vesting expected by January 1, 2027. The options have an expiration date of January 31, 2036, providing a long-term incentive.

Management Comments

• Director Jill M. Quigley elected to receive stock options in lieu of her $45,000 cash retainer fee for 2026, demonstrating a preference for equity-based compensation.

Industry Context

StockSavvy.ai notes that it is a common practice for non-employee directors in the biotechnology and pharmaceutical sectors to receive a portion, or sometimes all, of their compensation in the form of equity. This strategy is widely adopted to align the interests of the board members with those of the shareholders, particularly in growth-oriented companies like Terns Pharmaceuticals, where long-term value creation is paramount.

Comparison to Industry Standards

• The practice of non-employee directors electing equity over cash compensation is a standard corporate governance mechanism across various industries, including biotech, to foster alignment with shareholder interests.
• Many publicly traded companies, such as Moderna (MRNA) or BioNTech (BNTX), utilize similar equity compensation structures for their non-executive directors, often involving restricted stock units (RSUs) or stock options with multi-year vesting schedules.
• The specific value of $45,000 for a non-employee director's annual retainer, whether in cash or equity, falls within typical ranges for small to mid-cap biotechnology companies, though it can vary significantly based on company size, stage, and board responsibilities.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Director Jill M. Quigley in lieu of a cash retainer constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The decision by a director to accept equity compensation aligns their financial incentives with shareholder value creation, potentially leading to more shareholder-friendly decisions.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The acquired stock options will vest monthly over the next year, with full vesting by January 1, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction related to director compensation. While the director's choice for equity over cash is a positive signal of alignment, it does not represent a material event that would fundamentally alter the company's valuation or investment thesis. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not warrant a change in investment strategy.

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Stock Option, Director Compensation, Equity Compensation, Corporate Governance